Biotech Values

[biomaven0]

Current Abraxane sales are around $300m, but growing at 25% a year. If the drug succeeds in other indications like lung and pancreatic (it has a good shot in both in my view), then peak sales in excess of $2 billion are plausible.

CELG just paid around $2.8 billion plus some milestones for essentially Abraxane alone - the rest of the company isn't much at this point.

Peter